Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses
Top Cited Papers
- 17 February 2021
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 50 (7), 4514-4540
- https://doi.org/10.1039/d0cs01084g
Abstract
During the last forty years we have witnessed impressive advances in the field of antiviral drug discovery culminating with the introduction of therapies able to stop human immunodeficiency virus (HIV) replication, or cure hepatitis C virus infections in people suffering from liver disease. However, there are important viral diseases without effective treatments, and the emergence of drug resistance threatens the efficacy of successful therapies used today. In this review, we discuss strategies to discover antiviral compounds specifically designed to combat drug resistance. Currently, efforts in this field are focused on targeted proteins (e.g. multi-target drug design strategies), but also on drug conformation (either improving drug positioning in the binding pocket or introducing conformational constraints), in the introduction or exploitation of new binding sites, or in strengthening interaction forces through the introduction of multiple hydrogen bonds, covalent binding, halogen bonds, additional van der Waals forces or multivalent binding. Among the new developments, proteolysis targeting chimeras (PROTACs) have emerged as a valid approach taking advantage of intracellular mechanisms involving protein degradation by the ubiquitin-proteasome system. Finally, several molecules targeting host factors (e.g. human dihydroorotate dehydrogenase and DEAD-box polypeptide 3) have been identified as broad-spectrum antiviral compounds. Implementation of herein described medicinal chemistry strategies are expected to contribute to the discovery of new drugs effective against current and future threats due to emerging and re-emerging viral pandemics.Funding Information
- National Natural Science Foundation of China (81973181, 81773574)
- Consejo Superior de Investigaciones Científicas (2019AEP001)
- Key Technology Research and Development Program of Shandong (2019JZZY021011, 2017CXGC1401)
- Ministerio de Ciencia, Innovación y Universidades (BIO2016-76716-R (AEI/FEDER, UE)), PID2019-104176RB-I00/AEI/10.13039/501100011033)
- Fundación Ramón Areces
This publication has 233 references indexed in Scilit:
- Testing the Substrate-Envelope Hypothesis with Designed Pairs of CompoundsACS Chemical Biology, 2013
- Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H ActivityBiology, 2012
- Review and management of drug interactions with boceprevir and telaprevirJournal of Hepatology, 2012
- Computationally-Guided Optimization of a Docking Hit to Yield Catechol Diethers as Potent Anti-HIV AgentsJournal of Medicinal Chemistry, 2011
- Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor bindingProceedings of the National Academy of Sciences of the United States of America, 2010
- Cellular Networks Involved in the Influenza Virus Life CycleCell Host & Microbe, 2010
- Viral Resistance in Hepatitis B: Prevalence and ManagementCurrent Gastroenterology Reports, 2010
- Targeting the cancer kinome through polypharmacologyNature Reviews Cancer, 2010
- Discovery of Wild-Type and Y181C Mutant Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors Using Virtual Screening with Multiple Protein StructuresJournal of Chemical Information and Modeling, 2009
- Treatment of hantavirus pulmonary syndromeAntiviral Research, 2008